Located in Jinan City, Shandong Province, Qilu Pharmaceutical is one of the leading pharmaceutical companies in China. Qilu focuses on the development, manufacturing and marketing of generic drugs and active pharmaceutical ingredients(APIs) in therapeutic areas including but not limited to Oncology, Cerebrovascular & Cardiovascular, Anti-infections, Psychological & Neurological Systems, Respiratory System, and Ophthalmological Diseases. Qilu has more than 15,000 employees, 70% of whom have a college degree or above
Qilu Pharmaceutical consistently focuses on revolutionary development strategies guided by market demand and product innovation. Qilu has established extensive cooperation with domestic and international partners on multiple R&D projects. Devoted to the cultivation of talent, Qilu has invested in a highly qualified R&D team and efficient R&D capabilities. The 200+ new drug products successfully developed by Qilu constitutes as a large part of future production and sales for Qilu Pharmaceutical and partners. A number of technological achievements have garnered national and provincial scientific and technological progress awards for Qilu.
Qilu Pharmaceutical currently has nine manufacturing sites for finished dosage forms, chemical synthesis, genetic-engineering, fermentation and other products。 These modern production sites incorporate automated production lines while utilizing key equipment and analytical instruments from leading suppliers all over the world。 As a result, Qilu has been one of the leading global suppliers with substantial manufacturing capacity for top quality products。
Qilu Pharmaceutical has always been committed to providing high-quality products to patients and society. Thanks to the integrated and stringent system of quality control and quality assurance, the Company has been the leader of cGMP implementation in China. Its comprehensive finished dosages, sterile APIs and non-sterile APIs (fermentation and chemical synthesis) have been approved by USFDA, European Medicines Agency (EMA), Therapeutic Goods Administration (TGA) of Australia, Medicines and Healthcare products Regulatory Agency (MHRA) of UK, PMDA of Japan, and other national regulatory authorities.
Qilu Pharmaceutical has an integrated product portfolio and value chain with over 200 launched products。 The Company has established a comprehensive domestic and overseas sales network which covers North and South Americas, Europe, Asia, Australia, New Zealand, CIS (Commonwealth of Independent States) Countries, South Africa and the Middle East。 Qilu has more than 15,000 employees, 70% of whom have a college degree or above。